Table 4.

Analysis of covariance (ANCOVA) for change from baseline for weeks 6 and 12 in SF-12v2: physical component score among seropositive patients (positive values denote improvement).

	Week 6				Week 12
Treatment Group	LS-Mean	SE	95% CI	P value	LS-Mean	SE	95% CI	P value
Placebo (PBO)	3.2	3.0	(−2.8, 9.2)		6.5	2.9	(0.8, 12.3)
600 - PBO	7.5	4.9	(−2.2, 17.1)	0.129	3.8	4.7	(−5.6, 13.1)	0.424
900 - PBO	14.2	6.5	(1.3, 27.1)	0.031	−1.0	6.4	(−13.7, 11.7)	0.876
(600+900) - PBO	10.8	4.6	(1.7, 19.9)	0.020	1.4	4.5	(−7.5, 10.3)	0.755